Zuranolone

ZURZUVAE was approved by the FDA in August 2023 as the first-and-only oral treatment specifically indicated for adults with postpartum depression (PPD). Zuranolone is a next-generation positive allosteric modulator (PAM) of GABAA receptors being evaluated as a treatment for various affective disorders.